Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Biogen’s SPINRAZA Wins FDA Approval | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Biogen’s SPINRAZA Wins FDA Approval

Becomes the first and only treatment approved in the U.S. for SMA

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biogen’s SPINRAZA (nusinersen) has been approved by the FDA for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
 
The drug was under Priority Review and is the first and only treatment approved in the U.S. for SMA, a leading genetic cause of death in infants and toddlers that is marked by progressive, debilitating muscle weakness.
 
The approval was based on positive results from multiple clinical studies in more than 170 patients.  In ENDEAR, a pivotal controlled clinical study, patients treated with SPINRAZA achieved and sustained clinically meaningful improvement in motor function compared to untreated study participants. Also, a greater percent of patients on SPINRAZA survived compared to untreated patients. In open-label studies, some patients achieved milestones such as ability to sit unassisted, stand or walk and maintained milestones at ages when they would be expected to be lost. These findings support the effectiveness of SPINRAZA across the range of SMA patients and support the early initiation of treatment.
  

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics